FY2017 EPS Estimates for Celldex Therapeutics, Inc. (CLDX) Boosted by Cantor Fitzgerald

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Research analysts at Cantor Fitzgerald lifted their FY2017 EPS estimates for shares of Celldex Therapeutics in a report issued on Tuesday, Zacks Investment Research reports. Cantor Fitzgerald analyst M. Goldstein now forecasts that the biopharmaceutical company will earn ($1.23) per share for the year, up from their prior estimate of ($1.24).

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Tuesday, March 14th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. The company had revenue of $1.87 million for the quarter, compared to the consensus estimate of $1.10 million. Celldex Therapeutics had a negative return on equity of 51.46% and a negative net margin of 1,923.41%. The firm’s revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.33) EPS.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2017/04/21/brokers-offer-predictions-for-celldex-therapeutics-inc-s-fy2017-earnings-cldx-updated-updated.html.

Earnings History and Estimates for Celldex Therapeutics (NASDAQ:CLDX)

Several other equities analysts have also issued reports on CLDX. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Celldex Therapeutics in a report on Wednesday, March 15th. Jefferies Group LLC lowered their target price on shares of Celldex Therapeutics from $5.00 to $4.00 and set a “hold” rating for the company in a report on Wednesday, March 15th. Zacks Investment Research upgraded shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a report on Tuesday, January 17th. Finally, Aegis reissued a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, March 21st. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Celldex Therapeutics currently has an average rating of “Buy” and a consensus price target of $7.63.

Shares of Celldex Therapeutics (NASDAQ:CLDX) traded down 1.84% on Thursday, hitting $3.20. The stock had a trading volume of 1,177,814 shares. The firm has a 50 day moving average of $3.39 and a 200-day moving average of $3.60. The firm’s market capitalization is $394.28 million. Celldex Therapeutics has a 1-year low of $2.85 and a 1-year high of $5.13.

Several large investors have recently made changes to their positions in the stock. Marcus Capital LLC increased its stake in Celldex Therapeutics by 0.5% in the third quarter. Marcus Capital LLC now owns 112,200 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 600 shares during the period. Teachers Advisors LLC increased its stake in Celldex Therapeutics by 0.9% in the fourth quarter. Teachers Advisors LLC now owns 167,582 shares of the biopharmaceutical company’s stock worth $593,000 after buying an additional 1,433 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Celldex Therapeutics by 0.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 375,573 shares of the biopharmaceutical company’s stock worth $1,517,000 after buying an additional 2,507 shares during the period. Creative Planning increased its stake in Celldex Therapeutics by 6.1% in the first quarter. Creative Planning now owns 71,420 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 4,084 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in Celldex Therapeutics by 12.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 93,569 shares of the biopharmaceutical company’s stock worth $331,000 after buying an additional 10,427 shares during the period. 55.99% of the stock is owned by institutional investors.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

5 Day Chart for NASDAQ:CLDX

Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply